title: Intermittent parathyroid hormone administration improves periodontal healing in rats.
abstract: BACKGROUND
  Intermittent administration of parathyroid hormone (PTH) promotes new bone formation in patients with osteoporosis and bone fractures. It was shown previously that PTH also reduces periodontitis-related bone loss. The aim of this study is to evaluate the effect of treatment with PTH on periodontal healing in rats.
  
  
  METHODS
  Fenestration defects were created at the buccal surface of the distal root of the mandibular first molars, and both periodontal ligament (PDL) and cementum were removed. Animals were then assigned to two groups (eight animals per group): group 1: control, placebo administration; and group 2: test, human PTH (hPTH) 1-34 administration at a concentration of 40 μg/kg. For both groups, the animals were injected every 2 days, and the animals were sacrificed at 14 and 21 days after surgery. Specimens were harvested and processed for routine decalcified histologic sections. The following parameters were assessed: 1) remaining bone defect extension (RBDE); 2) newly formed bone density (NFBD); 3) total callus area (TCA); 4) osteoclast number (ON) in the callus region; and 5) newly formed dental cementum-like tissue (NFC). Birefringence of root PDL reattachment was also evaluated.
  
  
  RESULTS
  Birefringence analysis showed root PDL reattachment for both groups 21 days after treatment. Intermittent hPTH 1-34 administration decreased RBDE (P <0.01) and increased NFBD (P <0.01), TCA (P <0.01), area of NFC (P <0.01), and ON in the callus region (P <0.01).
  
  
  CONCLUSIONS
  Within the limits of the present study, intermittent administration of hPTH 1-34 led to an enhanced periodontal healing process compared with non-treated animals.
authors.affiliation: Division of Histology and Embryology, Federal University of Piauí, Parnaíba, Piauí, Brazil.
authors.forename: Daniel Fernando Pereira
authors.initials: DF
authors.lastname: Vasconcelos
authors.forename: Marcelo Rocha
authors.initials: MR
authors.lastname: Marques
authors.forename: Bruno Braga
authors.initials: BB
authors.lastname: Benatti
authors.forename: Silvana Pereira
authors.initials: SP
authors.lastname: Barros
authors.forename: Francisco Humberto
authors.initials: FH
authors.lastname: Nociti
authors.forename: Pedro Duarte
authors.initials: PD
authors.lastname: Novaes
mesh_terms: D000135:Acid Phosphatase / Q000032:analysis; D059250:Administration, Metronomic; D016301:Alveolar Bone Loss / Q000188:drug therapy*; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D002146:Bony Callus / Q000187:drug effects / Q000473:pathology; D002452:Cell Count; D025021:Cementogenesis / Q000187:drug effects; D003739:Dental Cementum / Q000187:drug effects / Q000473:pathology; D007279:Injections, Subcutaneous; D007527:Isoenzymes / Q000032:analysis; D008297:Male; D008336:Mandibular Diseases / Q000188:drug therapy; D010010:Osteoclasts / Q000187:drug effects / Q000473:pathology; D010012:Osteogenesis / Q000187:drug effects; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D010513:Periodontal Ligament / Q000187:drug effects / Q000473:pathology; D010919:Placebos; D051381:Rats; D017208:Rats, Wistar; D000071681:Tartrate-Resistant Acid Phosphatase; D013997:Time Factors; D014092:Tooth Root / Q000187:drug effects / Q000473:pathology; D014945:Wound Healing / Q000187:drug effects
chemical_list: D007527:Isoenzymes; D010281:Parathyroid Hormone; D010919:Placebos; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase